{
    "clinical_study": {
        "@rank": "43684", 
        "arm_group": {
            "arm_group_label": "Azilsartan 20mg to 40mg, orally, once daily"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of long-term use of\n      azilsartan tablets (Azilva Tablets) in patients with hypertension in a routine clinical\n      setting."
        }, 
        "brief_title": "Azilsartan Tablets Special Drug Use Surveillance: Long-term Use", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This surveillance was designed to evaluate the safety and efficacy of long-term use of\n      azilsartan tablets (Azilva Tablets) in hypertensive patients in daily medical practice.\n\n      The usual dosage for adult is 20 mg of azilsartan administered orally once daily. The dose\n      can be  adjusted according to the patient's age and condition. ,The maximum daily dose is 40\n      mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypertensive patients\n\n        Exclusion Criteria:\n\n          -  1. Patients with a history of hypersensitivity to any of the ingredients of\n             Azilsartan 2. Patients who are pregnant or having possibilities of being pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hypertension"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092025", 
            "org_study_id": "279-011", 
            "secondary_id": "JapicCTI-142441"
        }, 
        "intervention": {
            "arm_group_label": "Azilsartan 20mg to 40mg, orally, once daily", 
            "description": "Azilsartan tablets", 
            "intervention_name": "Azilsartan", 
            "intervention_type": "Drug", 
            "other_name": "Azilva Tablets"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Azilsartan Tablets Special Drug Use Surveillance: Long-term Use", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse drug reactions observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with administration of azilsartan whether or not it was considered related to the treatment. Among these, events which are considered to have a causal relationship with azilsartan are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tabulation of actual measured value and changes  from baseline at each test time point in blood pressure in daily medical practice (test value at each test time point after baseline - test value at baseline)", 
            "measure": "Change from baseline in blood pressure", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and Month 12"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}